Ascendis Pharma (ASND) analyst forecast and price target
Analyst forecast
Consensus of 21 analyst ratings
Based on 13 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Maintained | Overweight | $300.00 | Sep 25, 2026 |
| Raymond James | Downgraded | Strong Buy → Outperform | $287.00 | Sep 15, 2026 |
| Oppenheimer | Maintained | Outperform | $312.00 from $304.00 | Sep 2, 2026 |
| Wedbush | Maintained | Outperform | $327.00 | Sep 1, 2026 |
| Morgan Stanley | Maintained | Overweight | $273.00 from $275.00 | Sep 1, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $344.00 from $345.00 | Aug 31, 2026 |
| Stifel | Maintained | Buy | $326.00 from $328.00 | Aug 31, 2026 |
| B of A Securities | Maintained | Buy | $304.00 from $306.00 | Aug 31, 2026 |
| Jefferies | Maintained | Buy | $330.00 from $333.00 | Aug 31, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $345.00 | Aug 27, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $319.00 | Aug 19, 2026 |
| Barclays | Maintained | Overweight | $329.00 from $345.00 | Aug 14, 2026 |
| RBC Capital | Maintained | Outperform | $290.00 from $280.00 | Aug 14, 2026 |
| TD Cowen | Maintained | Buy | $341.00 from $325.00 | Aug 14, 2026 |
| Morgan Stanley | Maintained | Overweight | $275.00 from $256.00 | Jul 23, 2026 |
| RBC Capital | Maintained | Outperform | $280.00 from $275.00 | Jul 7, 2026 |
| Citigroup | Initiated Coverage | Buy | $355.00 | May 19, 2026 |
| Evercore ISI Group | Maintained | Outperform | $329.00 from $324.00 | May 15, 2026 |
| Barclays | Maintained | Overweight | $345.00 from $342.00 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $326.00 from $330.00 | May 8, 2026 |
Frequently asked questions
What is the price target for ASND stock?
The average 12-month analyst price target for Ascendis Pharma (ASND) is $314.00, with a high estimate of $344.00 and a low of $273.00, across 13 analysts.
Is ASND a buy, sell, or hold?
Analysts covering Ascendis Pharma currently average a Buy rating: 21 buy, 0 hold and 0 sell, from 21 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ASND?
The average price target of $314.00 implies 38.33% upside from the last price of $227.00.
What is the latest analyst rating on ASND?
On Sep 25, 2026, Cantor Fitzgerald maintained Ascendis Pharma at Overweight with a price target of $300.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.